Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-01
2008-07-01
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S247000
Reexamination Certificate
active
07393870
ABSTRACT:
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
REFERENCES:
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 6316635 (2001-11-01), Tang et al.
patent: 19924401 (2000-11-01), None
patent: 91/15495 (1991-10-01), None
patent: 92/20642 (1992-11-01), None
patent: 92/21660 (1992-12-01), None
patent: 94/03427 (1994-02-01), None
patent: 94/10202 (1994-05-01), None
patent: 94/14808 (1994-07-01), None
patent: WO 00/12084 (2000-03-01), None
patent: WO 00/56710 (2000-09-01), None
Science (1999), vol. 286, 531-537.
Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Plowman et al, “Receptor Tyrosine Kinases as Targets for Drug Intervention”, DN&P 7(6) Aug. 1994: 334-339.
Bolen, “Nonreceptor tyrosine protein kinases”, Oncogen 8: 2025-2031,1993.
Kendall et al, “Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor”, Proc. Nat'l Acad. Sci 90: 10705-09,1994.
Kim et al, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature 362: 841-844,1993.
Jellinek et al, “Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor”, Biochemistry 33: 10450-56, (1994).
Takano et al, “Inhibition of Angiogenesis by a Novel Diaminoanthraquinone that Inhibits Protein Kinase”, Mol. Bio. Cell 4: 358A,1992.
Kinsella et al, “Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel”, Exp. Cell Res. 199: 56-62,1992.
Wright et al, “Inhibition of Angiogenesis In Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032”, J. Cellular Phys. 152: 448-57,1992.
Mariani et al, “Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor”, Proc. Am. Assoc. Cancer Res. 35: 2268,1994.
Castro et al , “Quantitative Image Analysis of Laser-induced Choroidal Neovascularization in Rat”, Exp. Eye Res. 2000; 71:523-55.
McMurry, John, Organic Chemistry Fifth Edition, Brooks/Cole, (2000), p. 198.
Hasan et al, VEGF antagonists, Expert Opin. Biol. Ther. (2001) 1(4):703-718.
Andrews Steven W.
Wurster Julie A.
Allergan Inc.
Anderson Rebecca L
German Joel B.
Stathakis Dean G.
Voet Martin A.
LandOfFree
3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2756262